Precision oncology benefits from effective early phase drug discovery decisions. Recently,
drugging inactive protein conformations has shown impressive successes, raising the …

Identification of protein mutations that drive cancer is a major challenge. A primary reason is
that driver mutations are principally identified by their high frequency even though they can …

Understanding why driver mutations that promote cancer are sometimes rare is important for
precision medicine since it would help in their identification. Driver mutations are largely …

Most of the significant recent advances in cancer treatment have been based on the great
strides that have been made in our understanding of the underlying biology of the disease …

Analyses of cancer landscapes have established multiple activating mutations prompting
deliberations on the minimal number required for driving cancer [1]. These are likely to …

We critically survey the paradigms of molecularly targeted cancer therapy in light of systems-
level observations on tumor robustness and resilience. Multipronged attacks covering …

Cancer often arises when normal cellular growth goes awry due to defects in critical signal
transduction pathways. A growing number of inhibitors that target specific components of …

The success of mechanism-based drug discovery depends on the definition of the drug
target. This definition becomes even more important as we try to link drug response to …

The emergence of tumour-specific, molecularly targeted agents signifies a paradigm shift in
cancer therapy, with less reliance on drugs that non-discriminately kill tumour and host cells …

Therapeutic management of cancer has undergone tremendous conceptual advance over
the last couple of decades. Not only are we better acquainted with the intricate mechanisms …